COVID-19 test kits na likha ng UP-NIH binawi sa merkado

By Dona Dominguez-Cargullo May 21, 2020 - 12:15 PM

Hindi muna available para sa commercial use ang test kits na nilikha ng University of the Philippines – National Institutes for Health (UP-NIH).

Ito ay matapos makitaan ng “minor defect” ang test kits ayon sa Food and Drug Administration (FDA).

Sinabi ni FDA Director-General at DOH Undersecretary Eric Domingo binawi muna sa merakdo ang test kits.

Magugunitang inaprubahan ng FDA ang locally-made kits para sa commercial use noong Abril.

Pero nang isailalim sa validation ng Research Institute for Tropical Medicine (RITM) natuklasan na 30% ng test kits ay naglabas ng “indeterminate” results.

Ang 30% ng mga samples ay kinailangang isailalim sa repeat test.

Sinabi ni Domingo, bagaman accurate naman ang resulta ng test, may delay kung ito ang gagamitin dahil 30% ng resulta nito ay kailangang ulitin.

Ayon naman kay Health Undersecretary Maria Rosario Vergeire nasa final stages na ang UP-NIH para maitama ang natukoy na deficiency sa test kits.

 

 

TAGS: covid pandemic, COVID-19, department of health, FDA, general community quarantine, Health, Inquirer News, Modified enhanced community quarantine, News in the Philippines, Radyo Inquirer, State of Emergency, Tagalog breaking news, tagalog news website, test kits, University of the Philippines – National Institutes for Health, covid pandemic, COVID-19, department of health, FDA, general community quarantine, Health, Inquirer News, Modified enhanced community quarantine, News in the Philippines, Radyo Inquirer, State of Emergency, Tagalog breaking news, tagalog news website, test kits, University of the Philippines – National Institutes for Health

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.